Lanean...
Can a physician predict the clinical response to first-line immunomodulatory treatment in relapsing–remitting multiple sclerosis?
BACKGROUND: Decreased relapse rate and slower disease progression have been reported with long-term use of immunomodulatory treatments (IMTs, interferon beta or glatiramer acetate) in relapsing–remitting multiple sclerosis. There are, however, patients who do not respond to such treatments, and they...
Gorde:
| Egile Nagusiak: | , , , , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Dove Medical Press
2012
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3484901/ https://ncbi.nlm.nih.gov/pubmed/23118540 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/NDT.S36771 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|